Prostate cancer screening: guidelines review and laboratory issues.
clinical practice guidelines
prostate cancer
prostate-specific antigen (PSA)
screening
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
25 Sep 2019
25 Sep 2019
Historique:
received:
22
11
2018
accepted:
21
04
2019
pubmed:
24
5
2019
medline:
18
8
2020
entrez:
24
5
2019
Statut:
ppublish
Résumé
Background Prostate-specific antigen (PSA) remains as the most used biomarker in the detection of early prostate cancer (PCa). Clinical practice guidelines (CPGs) are produced to facilitate incorporation of evidence into clinical practice. This is particularly useful when PCa screening remains controversial and guidelines diverge among different medical institutions, although opportunistic screening is not recommended. Methods We performed a systematic review of guidelines about PCa screening using PSA. Guidelines published since 2008 were included in this study. The most updated version of these CPGs was used for the evaluation. Results Twenty-two guidelines were selected for review. In 59% of these guidelines, recommendations were graded according to level of evidence (n = 13), but only 18% of the guidelines provided clear algorithms (n = 4). Each CPG was assessed using a checklist of laboratory issues, including pre-analytical, analytical, and post-analytical factors. We found that laboratory medicine specialists participate in 9% of the guidelines reviewed (n = 2) and laboratory issues were frequently omitted. We remarked that information concerning the consequences of World Health Organization (WHO) standard in PSA testing was considered by only two of 22 CPGs evaluated in this study. Conclusions We concluded that the quality of PCa early detection guidelines could be improved properly considering the laboratory issues in their development.
Identifiants
pubmed: 31120856
doi: 10.1515/cclm-2018-1252
pii: cclm-2018-1252
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1474-1487Références
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356–87.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–9.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–35.
Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762–71.
Schroeder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012;62:745–52.
Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol 2015;68:885–90.
Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer 2014;120:3519–26.
Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K. Prostate-Specific Antigen (PSA) screening and new biomarkers for prostate cancer (PCa). EJIFCC 2014;25:55–78.
Carlsson SV, Roobol MJ. What’s new in screening in 2015? Curr Opin Urol 2016;26:447–58.
Eapen RS, Herlemann A, Washington 3rd SL, Cooperberg MR. Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging. Curr Opin Urol 2017;27:205–9.
Giménez N, Filella X, Gavagnach M, Allué JA, Pedrazas D, Ferrer F, et al. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians]. Semergen 2018;44:409–19.
National Guidelines Clearinghouse. Available at: https://www.guideline.gov/help-and-about/search-browse/search-tips. Accessed: 5 Oct 2018.
Guidelines International Network Web site. Available at: https://www.g-i-n.net/. Accessed: 5 Oct 2018.
NICE. National Institute for Health and Care Excellence Web site. Available at: https://www.nice.org.uk/. Accessed: 5 Oct 2018.
Aakre KM, Langlois MR, Watine J, Barth JH, Baum H, Collinson P, et al. Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation. Clin Chem Lab Med 2013;51:1217–26.
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11–79.
Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T. The Japanese guideline for PCa screening. Jpn J Clin Oncol 2009;39:339–51.
Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. The Committee for Establishment of the Guidelines on Screening for Prostate Cancer and Japanese Urological Association. Int J Urol 2010;17:830–8.
Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society PCa Advisory Committee. CA Cancer J Clin 2010;60:70–98.
Izawa JI, Klotz L, Siemens DR, Kassouf W, So A, Jordan J, et al. Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J 2011;5:235–40.
Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012;30:3020–5.
Prostate Cancer Taskforce. Diagnosis and management of prostate cancer in New Zealand men: recommendations from the Prostate Cancer Taskforce. Wellington: Ministry of Health, 2012. Available at: http://www.prostate.org.nz/documents/diagnosis-management-prostate-cancer-nz-men_(3).pdf. Accessed: 9 Oct 2018.
Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Screening for PCa: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158:761–9.
Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, et al. The Melbourne Consensus Statement on the early detection of PCa. BJU Int 2014;113:186–8.
Cancer Screening. Guidelines for clinical care ambulatory. University of Michigan, 2014. Available at: https://www.med.umich.edu/1info/FHP/practiceguides/adult.cancer/cancergline.pdf. Accessed: 9 Oct 2018.
Recommendations on screening for prostate cancer with the prostate-specific antigen test. Canadian task force on preventive health care. Can Med Assoc J 2014;186:1225–34.
PSA Testing for Prostate Cancer in Asymptomatic Men Information for Health Practitioners. Australian Government. National Health and Medical Research Council, 2014. Available at: https://nhmrc.gov.au/sites/default/files/documents/reports/clinical%20guidelines/men4d-psa-testing-asymptomatic.pdf. Accessed: 9 Oct 2018.
National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment. London (UK): National Institute for Health and Care Excellence (NICE), 2014. Available at: https://www.nice.org.uk/guidance/cg175/evidence/full-guideline-191710765. Accessed: 9 Oct 2018.
Parker C, Gillessen S, Heidenreich A, Horwich A, on behalf of the ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Supplement 5):v69–77.
Alberta Health Services. Prostate Cancer. Clinical practice guideline Alberta, 2015.
Livingston CJ, Freeman RJ, Mohammad A, Costales VC, Titus TM, Harvey BJ, et al. Choosing Wisely® in preventive medicine: the American College of Preventive Medicine’s Top 5 List of Recommendations. Am J Prev Med 2016;51:141–9.
Vickers AJ, Eastham JA, Scardino PT, Lilja H. The Memorial Sloan Kettering Cancer Center recommendations for PCa screening. Urology 2016;91:12–8.
The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 9th edn. East Melbourne, Vic: RACGP, 2016. Available at: https://www.racgp.org.au/your-practice/guidelines/redbook/9-early-detection-of-cancers/91-prostate-cancer/. Accessed: 9 Oct 2018.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618–29.
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greeneet KL, et al. Early detection of prostate cancer. American Urological Association, 2018. Available at: https://www.auanet.org/guidelines/prostate-cancer-early-detection-guideline. Accessed: 19 March 2019.
NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection. Version 2.2018, April 2018. Available at: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed: 9 Oct 2018.
Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. J Am Med Assoc 2018;319:1901–13.
Schmeller N. Clinical value of PSA. Bremen: UNI-Med Verlag, 2005.
Sturgeon CM, Ellis AR. Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems. Clin Chim Acta 2007;381:8–92.
Rafferty B, Rigsby P, Rose M, Stamey T, Gaines DR. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 2000;46:1310–7.
Roddam AW, Rimmer J, Nickerson C, Ward AM. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 2006;43:35–48.
Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 2006;52:1568–74.
Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52:59–64.
Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182:2232–41.
Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst 2007;99:1510–5.
Slev PR, La’ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol 2008;129:952–8.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124–37.
Stephan C, Köpke T, Semjonow A, Lein M, Deger S, Schrader M, et al. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med 2009;47:1325–31.
Mottet N, Bellmunt J, Briers E, van den Bergh RC, Bolla M, van Casteren NJ, et al. EAU Guidelines on prostate cancer. Available at: https://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf. Accessed: 10 Oct 2018.
Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate specific antigen values. Prostate Suppl 1996;7:3–16.
Moyer VA, U.S. Preventive Services Task Force. Screening for PCa: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–34.
Aslani A, Minnillo BJ, Johnson B, Cherullo EE, Ponsky LE, Abouassaly R. The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol 2014;191:1737–42.
Cohn JA, Wang CE, Lakeman JC, Silverstein JC, Brendler CB, Novakovic KR, et al. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 2014;32:41.e23–30.
Ong MS, Mandl KD. Trends in Prostate-Specific Antigen screening and prostate cancer interventions 3 years after the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2017;166:451–2.
Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol 2017;14:26–37.
Calonge N, Petitti DB, DeWitt TG, Dietrich AJ, Gregory KD, Harris R, et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:185–91.
Heijnsdijk EA, Denham D, de Koning HJ. The cost-effectiveness of prostate cancer detection with the use of Prostate Health Index. Value Health 2016;19:153–7.
Mathieu R, Castelli C, Fardoun T, Peyronnet B, Shariat SF, Bensalah K, et al. Cost analysis of prostate cancer detection including the prostate health index (PHI). World J Urol 2019;37:481–7.
Palenius E, Bonnevier E. Evaluation of the cost-effectiveness of novel tests in the screening and diagnostic. Phases of prostate cancer compared to current practice. Lund University, 2017.
Gupta M, McCauley J, Farkas A, Gudeloglu A, Neuberger MM, Ho YY, et al. Clinical practice guidelines on prostate cancer: a critical appraisal. J Urol 2015;193:1153–8.
Stephan C. WHO standardization of PSA tests: clinical consequences. Nat Rev Urol 2009;6:303–5.
Foj L, Filella X, Alcover J, Augé JM, Escudero JM, Molina R. Variability of assay methods for total and free PSA after WHO standardization. Tumor Biol 2014;35:1867–73.